Related Experiment Video

Updated: Jun 13, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K

An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)

Daniel Armstrong1, Maha Hanafi1,2, Brendan Frett1

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Expert Opinion on Therapeutic Patents
|June 12, 2025
PubMed
Abstract

Insights

Recent patents reveal novel small-molecule Rearranged during transfection (RET) inhibitors designed to overcome resistance and improve safety. These next-generation drugs offer a critical advancement in precision oncology for RET-driven cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Rearranged during transfection (RET) is a receptor tyrosine kinase vital for cell signaling.
  • Alterations in RET, including mutations and fusions, are implicated in cancer development.
  • Selective RET inhibitors have emerged as a precision oncology strategy.

Purpose of the Study:

  • To review recent innovations in RET inhibitor development.
  • To focus on small-molecule patents from 2022-2024.
  • To summarize structural classes, target profiles, and advantages of new compounds, especially in overcoming resistance.

Main Methods:

  • Comprehensive literature search using SciFinder and PatentScope.
  • Keywords: 'RET', 'RET inhibitor'.
  • Analysis of patented small-molecule RET inhibitors.

Main Results:

  • Identification of novel structural classes of RET inhibitors.
  • Characterization of target profiles for new compounds.
  • Highlighting compounds designed to address known resistance mechanisms.

Conclusions:

  • Next-generation RET inhibitors are crucial for advancing cancer treatment.
  • New patented compounds show promise in overcoming limitations of current therapies.
  • Continued development of selective RET inhibitors is a key frontier in precision oncology.
Keywords:
RETkinasekinase inhibitorprecision medicinetargeted therapy

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
5.9K